Novel HIV-1 vaccine candidates invented at Scripps Research to enter Phase 1 Clinical Trial
Following approval from Australia’s HREC, the clinical trial investigating UVAX-1107 and UXAX-1197 will initiate in January 2024. December 20, 2023, Scripps Research, La Jolla, CA Two HIV-1 vaccine candidates initially invented at Scripps Research and subsequently licensed to Uvax Bio, LLC, have received [...]
Trim the sugar: New HIV vaccine design improves immune response
Scripps Research vaccine candidate headed for clinical trials. April 19, 2023 LA JOLLA, CA— A new HIV vaccine from Scripps Research has shown a significantly improved ability to neutralize the virus in preclinical tests, and it will soon be studied in healthy people who volunteer [...]
Nanoparticle vaccine for COVID-19 spurs robust immune response in preclinical tests
September 21, 2020 - Scripps Research, La Jolla, CA In a new study that demonstrates the promise of a novel vaccine approach for COVID-19, Scripps Research scientist Jiang Zhu, PhD, showed that his protein nanoparticle technology successfully triggered a strong immune response in mice. Zhu, [...]
Researchers unveil promising hepatitis C vaccine design
April 15, 2020 - Scripps Research, La Jolla, CA A new design for a vaccine against hepatitis C virus (HCV) has shown promise in early tests, according to a study from scientists at Scripps Research. The scientists, who present their results on April 15 in [...]
cGMP Process Kickoff Meeting
March 25, 2019 - NIH Division of AIDS (DAIDS), ABL Inc, Ufovax Inc and Dr. Zhu (on behalf of Scripps Research) held a kickoff meeting to start the cGMP process development for the HIV-1 nanoparticle vaccines developed in Dr. Zhu's laboratory.
UFOVAX and Scripps Research Sign 5 Year Agreement
February 14, 2019 - Ufovax Inc signed a five-year agreement with Scripps Research to support vaccine development in Dr. Zhu's laboratory.